Klaria Pharma Calls General Meeting for Rights Issue and Articles of Association Amendment
Klaria Pharma Holding AB has called an Extraordinary General Meeting to decide on a rights issue of units and an amendment to its Articles of Association. The move aims to strengthen the company's financial position.
Klaria Pharma Holding AB announced it has convened an Extraordinary General Meeting (EGM) where shareholders will vote on a proposed rights issue of units and an amendment to the company's Articles of Association. The purpose of these measures is to strengthen Klaria Pharma's financial standing and support its ongoing development.
The Board of Directors resolved to call the EGM, indicating the importance of shareholder approval for the planned capital raise. The rights issue is intended to provide the company with additional capital to fund its operations and strategic initiatives.
Alongside the rights issue, the meeting will address changes to the Articles of Association, which are expected to align with the company's evolving corporate structure and financing plans. Further details regarding the terms of the rights issue will be disclosed in the official notice.
Klaria Pharma is a pharmaceutical company focused on drug development. Its activities primarily involve research and development in the pharmaceutical sector.